- Conditions
- Multiple Sclerosis
- Interventions
- ABT-874/Human monoclonal antibody against IL-12, Placebo
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 215 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 23 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 817–840
of 5,550
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Charcot-Marie-Tooth Disease
- Interventions
- (RS)-baclofen, naltrexone hydrochloride and D-sorbitol, Placebo
- Drug
- Lead sponsor
- Pharnext S.C.A.
- Other
- Eligibility
- 16 Years to 65 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Sacramento, California • New Britain, Connecticut + 16 more
- Conditions
- Urinary Bladder Neoplasms
- Interventions
- larotaxel (XRP9881), gemcitabine, cisplatin
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 337 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 52
- States / cities
- Anchorage, Alaska • Berkeley, California • Burbank, California + 46 more
- Conditions
- Alzheimer's Disease
- Interventions
- Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Lumbar Puncture (LP)
- Procedure
- Lead sponsor
- Alzheimer's Disease Cooperative Study (ADCS)
- Other
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 818 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2011
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 43 more
- Conditions
- Moderate to Severe Plaque Psoriasis
- Interventions
- No intervention
- Other
- Lead sponsor
- Janssen Biotech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Sacramento, California • Ann Arbor, Michigan + 6 more
- Conditions
- Breast Carcinoma, Colorectal Carcinoma, Lung Non-Small Cell Carcinoma, Melanoma, Non-Hodgkin Lymphoma
- Interventions
- Non-interventional Study
- Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 483
- States / cities
- Fairbanks, Alaska • Kingman, Arizona • Phoenix, Arizona + 376 more
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
- Interventions
- Bevacizumab, Everolimus, Laboratory Biomarker Analysis, Pharmacological Study
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 524
- States / cities
- Scottsdale, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 354 more
- Conditions
- Exercise-associated Hyponatremia
- Interventions
- Intravenous hypertonic Saline, Oral hypertonic saline
- Other
- Lead sponsor
- Western States Endurance Run Research Foundation
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Parkinson's Disease (PD)
- Interventions
- EC5026 oral tablet, Placebo
- Drug
- Lead sponsor
- EicOsis Human Health Inc.
- Industry
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
- Interventions
- Quality-of-Life Assessment, Questionnaire Administration
- Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 537
- States / cities
- Anchorage, Alaska • Hot Springs, Arkansas • Antioch, California + 343 more
- Conditions
- Duchenne Muscular Dystrophy (DMD)
- Interventions
- eteplirsen
- Drug
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- 7 Years to 16 Years · Male only
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 32 more
- Conditions
- ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
- Interventions
- Clinical Observation, Crizotinib, Laboratory Biomarker Analysis
- Other · Drug
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2036
- U.S. locations
- 1613
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 978 more
- Conditions
- Atopic Dermatitis
- Interventions
- Rocatinlimab, Placebo
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 746 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City West, Arizona + 36 more
- Conditions
- Geographic Atrophy
- Interventions
- NGM621, Sham Comparator
- Biological · Other
- Lead sponsor
- NGM Biopharmaceuticals, Inc
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 65
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 59 more
- Conditions
- Growth Hormone Deficiency
- Interventions
- Not listed
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 1 Day to 18 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Ischemic Stroke; Ischemic Attack, Transient
- Interventions
- Milvexian, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 12,523 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 127
- States / cities
- Mesa, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 102 more
- Conditions
- Overactive Bladder
- Interventions
- Solabegron modified release tablets, low dose, Solabegron modified release tablets, high dose, Matching Placebo
- Drug
- Lead sponsor
- Velicept Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 1,413 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 77
- States / cities
- Birmingham, Alabama • Guntersville, Alabama • Saraland, Alabama + 61 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Necitumumab, Gemcitabine, Cisplatin
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,093 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2024
- U.S. locations
- 15
- States / cities
- Chandler, Arizona • Fayetteville, Arkansas • Sacramento, California + 12 more
- Conditions
- Primary Sclerosing Cholangitis
- Interventions
- Cenicriviroc 150 mg
- Drug
- Lead sponsor
- Tobira Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 5
- States / cities
- La Jolla, California • Sacramento, California • San Francisco, California + 2 more
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Transformed B-Cell Non-Hodgkin Lymphoma
- Interventions
- Mogamulizumab, Pembrolizumab
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 8
- States / cities
- Sacramento, California • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
- Conditions
- Growth Hormone Deficiency in Children
- Interventions
- Somapacitan, Norditropin®
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- Up to 11 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Los Angeles, California • Madera, California + 24 more
- Conditions
- HIV-1 Infection
- Interventions
- Islatravir, Placebo to Islatravir, Doravirine, Placebo to Doravirine, Lamivudine, Placebo to Lamivudine, Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate, Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate, Doravirine/Islatravir
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 7 more
- Conditions
- Autism Spectrum Disorder
- Interventions
- Teams Leadership Institute (TLI), Motivational Enhancement (TIPS for Training), Classroom Pivotal Response Teaching (CPRT), An Individualized Mental Health Intervention for ASD (AIM HI), Team-Enhanced Teams Leadership Institute (TLI)
- Behavioral
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,206 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2027
- U.S. locations
- 3
- States / cities
- Sacramento, California • San Diego, California • Westwood, Los Angeles, California
- Conditions
- Wrinkles, Skin
- Interventions
- Almond Oil
- Other
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 40 Years and older · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Sacramento, California